Pomdoctor H1 2026 net loss widens to RMB 238.17 mln as share-based compensation rises
Pomdoctor said net revenue rose 6% to RMB 185 million for the six months ended June 30, 2026, while net loss widened to RMB 238.17 million on RMB 215.7 million of share-based compensation tied to marketing, administrative and R&D services.